Divi's Laboratories Limited (DIVISLAB)
Submission of transcript of Earnings Conference Call held on August 01, 2026
AI summary
- Q1 FY27 consolidated total income ₹3,144 Cr (+24% y-y); PAT ₹902 Cr (+65% y-y)
- Custom Synthesis contributed 60% of revenue; Generics 40%
- Ongoing capex projects nearing completion; validation batches progressing
- Peptide capacity expanding with new 3,000-liter SPPS installations
- Supply chain challenges persist; 3-month inventory buffer maintained
- Gross margin approx. 68% in Q1; full-year margin expected near last year's level
- Nutraceutical revenue ₹298 Cr (+19% y-y)
- Regulatory approvals key for commercial ramp-up of new projects
- Unit 3 supports backward integration; overall plant utilization ~85%
- Management targets sustained double-digit revenue growth for FY27
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 DIVISLAB — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add DIVISLAB to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Divi's Laboratories Limited
Important.
The summary above is generated automatically from Divi's Laboratories Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.